AGMB vs ALT: fair value comparison
AgomAb Therapeutics NV and Altimmune, Inc. · Updated 2026-10-19
AGMB reports in EUR, so no same-currency fair-value verdict is published for it. ALT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AGMB currently ranks higher by quality score.
| AGMB | ALT | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $8.65 | $2.20 |
| 12-month range | $8.65–$16.21 | $2.20–$6.18 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #216 of 301 Healthcare | #217 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AGMB fair value analysis · ALT fair value analysis